Skip to main content

Table S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Publication ,  Other
Paller, CJ; Zahurak, ML; Mandl, A; Metri, NA; Lalji, A; Heath, E; Kelly, WK; Hoimes, C; Barata, P; Taksey, J; Garrison, DA; Patra, K ...
March 26, 2025

<p>Table S3 shows Adverse Events Included in the Co-Primary Endpoint: All Occurrences</p>

Duke Scholars

DOI

Publication Date

March 26, 2025
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Paller, C. J., Zahurak, M. L., Mandl, A., Metri, N. A., Lalji, A., Heath, E., … Levine, M. (2025). Table S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. https://doi.org/10.1158/2767-9764.28672580
Paller, Channing J., Marianna L. Zahurak, Adel Mandl, Nicole A. Metri, Aliya Lalji, Elisabeth Heath, William K. Kelly, et al. “Table S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial,” March 26, 2025. https://doi.org/10.1158/2767-9764.28672580.
Paller CJ, Zahurak ML, Mandl A, Metri NA, Lalji A, Heath E, Kelly WK, Hoimes C, Barata P, Taksey J, Garrison DA, Patra K, Milne GL, Anders NM, Nauroth JM, Durham JN, Marshall CH, Markowski MC, Eisenberger MA, Antonarakis ES, Carducci MA, Denmeade SR, Levine M. Table S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. 2025.

DOI

Publication Date

March 26, 2025